Literature DB >> 20804886

End-stage liver disease: challenges and practice implications.

Lissi Hansen1, Anna Sasaki, Betsy Zucker.   

Abstract

As the seventh leading cause of death among people aged 25 to 64 years, end-stage liver disease (ESLD) affects many Americans in the most productive years of their lives. Despite the increasing number of individuals who are dying of ESLD, little is documented about their end of life challenges as the disease progresses. The purpose of this article is to highlight specific challenges for people with ESLD, their families, and their implications for health care providers: ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, malnutrition, altered drug metabolism, renal insufficiency and hyponatremia, hepatocellular carcinoma, and pain. The authors also present a case study to illustrate disease progression and difficulties facing patients, family members, and providers.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20804886     DOI: 10.1016/j.cnur.2010.03.005

Source DB:  PubMed          Journal:  Nurs Clin North Am        ISSN: 0029-6465            Impact factor:   1.208


  8 in total

1.  Symptom distress in patients with end-stage liver disease toward the end of life.

Authors:  Lissi Hansen; Michael C Leo; Michael F Chang; Atif Zaman; Willscott Naugler; Jonathan Schwartz
Journal:  Gastroenterol Nurs       Date:  2015 May-Jun       Impact factor: 0.978

2.  Pain and self-care behaviours in adult patients with end-stage liver disease: a longitudinal description.

Authors:  Lissi Hansen; Michael C Leo; Michael F Chang; Betsy L Zucker; Anna Sasaki
Journal:  J Palliat Care       Date:  2014       Impact factor: 2.250

3.  Palliative care for cirrhosis: a UK survey of health professionals' perceptions, current practice and future needs.

Authors:  Joseph Low; Victoria Vickerstaff; Sarah Davis; Julia Bichard; Lynda Greenslade; Katherine Hopkins; Aileen Marshall; Douglas Thorburn; Louise Jones
Journal:  Frontline Gastroenterol       Date:  2015-07-24

4.  Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis.

Authors:  A M Walling; S C Ahluwalia; N S Wenger; M Booth; C P Roth; K Lorenz; F Kanwal; S Dy; S M Asch
Journal:  Dig Dis Sci       Date:  2016-11-01       Impact factor: 3.487

5.  The effect of Self-Management Training on Self-Efficacy of Cirrhotic Patients Referring to Transplantation Center of Nemazee Hospital: A Randomized Controlled Clinical Trial.

Authors:  Parisa Mansouri; Maryam Ghadami; Seid Saeed Najafi; Shahrzad Yektatalab
Journal:  Int J Community Based Nurs Midwifery       Date:  2017-07

6.  In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT.

Authors:  Niklas Verloh; Ingo Einspieler; Kirsten Utpatel; Karin Menhart; Stefan Brunner; Frank Hofheinz; Jörg van den Hoff; Philipp Wiggermann; Matthias Evert; Christian Stroszczynski; Dirk Hellwig; Jirka Grosse
Journal:  EJNMMI Res       Date:  2018-11-09       Impact factor: 3.138

7.  Health-related quality of life and health literacy in patients with systemic mastocytosis and mast cell activation syndrome.

Authors:  Rupert Conrad; Martin Mücke; Tobias Jürgen Schmidt; Julia Sellin; Gerhard J Molderings
Journal:  Orphanet J Rare Dis       Date:  2022-07-29       Impact factor: 4.303

8.  Advanced chronic liver disease in the last year of life: a mixed methods study to understand how care in a specialist liver unit could be improved.

Authors:  Joseph Low; Sarah Davis; Victoria Vickerstaff; Lynda Greenslade; Katherine Hopkins; Andrew Langford; Aileen Marshall; Douglas Thorburn; Louise Jones
Journal:  BMJ Open       Date:  2017-08-29       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.